Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs. 2018;32(2):135–47. https://doi.org/10.1007/s40263-018-0494-8.

Article  CAS  PubMed  Google Scholar 

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

Book  Google Scholar 

Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486–7. https://doi.org/10.1001/archpsyc.1982.04290040080014.

Article  CAS  PubMed  Google Scholar 

Widschwendter CG, Hofer A. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. Curr Opin Psychiatry. 2019;32(3):179–84. https://doi.org/10.1097/yco.0000000000000491.

Article  PubMed  Google Scholar 

Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35–42.

Article  PubMed  Google Scholar 

Caroff SN, Ungvari GS, Cunningham Owens DG. Historical perspectives on tardive dyskinesia. J Neurol Sci. 2018;389:4–9. https://doi.org/10.1016/j.jns.2018.02.015.

Article  PubMed  Google Scholar 

Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. In: Weiner WJ, Tolosa E, editors. Handbook of clinical neurology. Elsevier; 2011. p. 601–16.

Google Scholar 

Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? Mov Disord. 2006;21(5):589–98. https://doi.org/10.1002/mds.20823.

Article  PubMed  Google Scholar 

Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry. 2008;69(10):1580–8. https://doi.org/10.4088/jcp.v69n1008.

Article  PubMed  Google Scholar 

Chong S-A, Tay JAM, Subramaniam M, Pek E, Machin D. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009;29(1):5–8. https://doi.org/10.1097/JCP.0b013e3181929f94.

Article  PubMed  Google Scholar 

Chong S-A, Remington G, Mahendran R, Chua H-C. Awareness of tardive dyskinesia in Asian patients with schizophrenia. J Clin Psychopharmacol. 2001;21(2):235–7.

Article  CAS  PubMed  Google Scholar 

Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76. https://doi.org/10.1007/s13311-013-0222-5.

Article  CAS  PubMed  Google Scholar 

Reich SG. Pearls: hyperkinetic movement disorders. Semin Neurol. 2010;30(1):15–22. https://doi.org/10.1055/s-0029-1245005.

Article  PubMed  Google Scholar 

Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94(2):118–24. https://doi.org/10.1111/j.1600-0447.1996.tb09835.x.

Article  CAS  PubMed  Google Scholar 

Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinetic Movements. 2014. https://doi.org/10.7916/D8MS3R8C.

Article  PubMed  PubMed Central  Google Scholar 

Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50(9):541–7. https://doi.org/10.1177/070674370505000907.

Article  PubMed  Google Scholar 

Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Pediatr Drugs. 2013;15(3):217–33. https://doi.org/10.1007/s40272-013-0024-6.

Article  Google Scholar 

Masi G, Liboni F. Management of schizophrenia in children and adolescents: focus on pharmacotherapy. Drugs. 2011;71(2):179–208. https://doi.org/10.2165/11585350-000000000-00000.

Article  CAS  PubMed  Google Scholar 

Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651–68. https://doi.org/10.2165/11592020-000000000-00000.

Article  PubMed  Google Scholar 

Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6. https://doi.org/10.1097/YCO.0b013e3282f53132.

Article  PubMed  Google Scholar 

Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17(5):647–56. https://doi.org/10.1089/cap.2006.0117.

Article  PubMed  Google Scholar 

Laboe C, Jain A, Cardiel SH. Masked tardive dyskinesia in the coronavirus disease 2019 era. Cureus. 2021;13(8): e16999. https://doi.org/10.7759/cureus.16999.

Article  PubMed  PubMed Central  Google Scholar 

Kakko K, Bjelogrlic-Laakso N, Pihlakoski L, Lehtimäki K, Järventausta K. Tardive dyskinesia should not be overlooked. J Child Adolesc Psychopharmacol. 2019;29(1):72–4. https://doi.org/10.1089/cap.2018.0084.

Article  PubMed  Google Scholar 

Kidd V. Risperidone-induced tardive dyskinesia in an autistic child. Prim Care Companion CNS Disord. 2018. https://doi.org/10.4088/PCC.18l02283.

Article  PubMed  Google Scholar 

Lamberti M, Di Rosa G, Cucinotta F, Pironti E, Galati C, Gagliano A. Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: a case report. Clin Psychopharmacol Neurosci. 2017;15(3):285–7. https://doi.org/10.9758/cpn.2017.15.3.285.

Article  PubMed  PubMed Central  Google Scholar 

Pérez CA, Garcia SS, Yu RD. Extrapyramidal symptoms as a result of risperidone discontinuation during combination therapy with methylphenidate in a pediatric patient. J Child Adolesc Psychopharmacol. 2016;26(2):182. https://doi.org/10.1089/cap.2015.0225.

Article  PubMed  Google Scholar 

Tunc Z, Celik G, Avci A, Tahiroglu A, Gamli I. Supplementation of vitamin E and N-acetylcysteine with quetiapine in tardive dyskinesia: a case report. Klinik Psikofarmakoloji Bulteni. 2014;24:S350.

Google Scholar 

Aggarwal S, Burnett P. Tardive dyskinesia with atypical antipsychotics in youth. Australas Psychiatry. 2013;21(5):507–8. https://doi.org/10.1177/1039856213492864.

Article  PubMed  Google Scholar 

Tufan AE, Bilici R, Ugurlu GK, Yilmaz S, Erdogan A. Tardive dyskinesia due to olanzapine in an adolescent with psychosis and its treatment with clozapine. Arch Neuropsychiatry. 2013;50(2):183–6.

Article  Google Scholar 

Kwon H. Tardive dyskinesia in an autistic patient treated with risperidone. Am J Psychiatry. 2004;161(4):757–8. https://doi.org/10.1176/appi.ajp.161.4.757-a.

Article  PubMed  Google Scholar 

Borchardt CM, Jensen C, Dean CE, Tori J. Case study: childhood-onset tardive dyskinesia versus choreoacanthocytosis. J Am Acad Child Adolesc Psychiatry. 2000;39(8):1055–8. https://doi.org/10.1097/00004583-200008000-00022.

Article  CAS  PubMed  Google Scholar 

Kumar S, Malone DM. Risperidone implicated in the onset of tardive dyskinesia in a young woman. Postgrad Med J. 2000;76(895):316–7. https://doi.org/10.1136/pmj.76.895.316.

Article  CAS  PubMed  PubMed Central